YOLFTbeta
Oncodesign Precision Medicine

Oncodesign Precision Medicine

ALOPM · PA · Healthcare / Biotechnology

0.259EUR+0.00 (+1.57%)

Price History

Full chart

Market Stats

Previous Close0.255
Open0.256
Day Range0.256 – 0.259
52-Week Range0.20 – 0.92
Volume101
Market Cap7.25M
P/E (TTM)1.27
Forward P/E0.00
EPS0.30
Dividend Yield0.00%
Beta-0.32
50-Day Avg0.2939
200-Day Avg0.4189

About

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Philippe Genne Ph.D.
  • Employees13
  • Headquarters18 Rue Jean Mazen, Dijon, France, 21000, France
  • Websitehttps://www.oncodesign.com

Leadership

  • Dr. Philippe Genne Ph.D.Chairman & CEO
  • Ms. Karine LignelChief Operating Officer · b. 1970
  • Dr. Jan Hoflack Ph.D.Chief Scientific Officer · b. 1960
  • Mr. Stephane GerartChief Information Officer · b. 1983
  • Sylvie Fernandes ForsterChief Legal Officer

Financials

Income Statement

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.41M3.83M7.98M1.07M207.04K261.15K
Growth (%)--13.13%+108.32%-86.57%-80.69%+26.13%
Cost of Revenue9.11M5.81M7.52M7.67M6.50M-9.47M
Gross Profit-4.70M-1.98M459.51K-6.60M-6.29M9.73M
Gross Margin-106.63%-51.62%5.76%-615.40%-3039.75%3726.13%
Operating Expense1.46M1.75M2.07M3.35M1.51M1.51M
Operating Income-6.17M-3.73M-1.61M-9.94M-7.81M8.22M
Operating Margin-139.82%-97.26%-20.17%-927.44%-3770.81%3146.92%
EBITDA---1.44M-9.46M-7.26M6.06M
EBITDA Margin---18.07%-882.10%-3508.37%2319.68%
Net Income-153.83K-2.94M-231.18K-8.09M-7.21M5.48M
Net Income Margin-3.49%-76.86%-2.90%-754.61%-3482.24%2098.32%
Interest Expense85.78K355.93K116.50K146.63K438.79K185.81K
Interest Expense % of Total Revenue1.95%9.29%1.46%13.68%211.94%71.15%

Balance Sheet

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.41M8.37M18.37M16.63M10.71M14.99M
Total Liabilities5.44M4.17M6.59M12.94M11.14M-37.89M
Total Equity6.97M4.20M11.78M3.69M-429.39K52.88M
Cash8.43M4.92M13.37M322.58K436.92K312.48K
Net Debt---8.50M7.14M6.05M

Cash Flow

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Capital Expenditure000000

Earnings

Report DateApr 23, 2025Jul 31, 2025Oct 9, 2025Apr 8, 2026
EPS Estimate0.000.000.000.00
EPS Actual0.000.000.540.00
Surprise----
Timing----

Key Statistics & Ratios

Market Cap7.25M
Enterprise Value9.12M
Trailing P/E1.27
Forward P/E0.00
Price / Sales4.00
Price / Book0.09
EPS0.30
Book Value0.315
Revenue (TTM)1.81M
Gross Profit (TTM)8.75M
EBITDA6.05M
Profit Margin302.27%
Operating Margin-379.86%
Return on Equity203.90%
Return on Assets27.76%
Shares Outstanding19.07M
Shares Float17.38M
Beta-0.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20092×
0.04Jul 6, 20090.09May 12, 2009
20081×
0.07Mar 31, 2008